Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 1;36(6):572-584.
doi: 10.1097/QCO.0000000000000975. Epub 2023 Oct 16.

Treatment approaches for severe Stenotrophomonas maltophilia infections

Maria F Mojica  1   2   3 , Robert A Bonomo  2   4   5 , David van Duin  6
Affiliations
Review

Treatment approaches for severe Stenotrophomonas maltophilia infections

Maria F Mojica et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: Stenotrophomonas maltophilia is an emerged opportunistic pathogen. Intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge. Herein, we provide an update on the most recent literature on treatment options for severe S. maltophilia infections.

Recent findings: Trimethoprim-sulfamethoxazole (SXT) is recognized as the first-line therapy for S. maltophilia infections. However, its clinical use is based on good in vitro activity and favorable clinical outcomes, rather than on solid minimum inhibitory concentration (MIC) correlations with pharmacokinetic/pharmacodynamics (PK/PD) and/or clinical outcomes. The same is true for other treatment options like levofloxacin (LVX) and minocycline (MIN). Recent PK/PD studies question the current clinical breakpoints for SXT, LVX, and MIN. Based on this, the latest guidance issued by the Infectious Diseases Society of America (IDSA) recommends using these agents only as part of a combination therapy. Alternatively, novel therapeutic options such as cefiderocol (FDC) and ceftazidime-avibactam plus aztreonam (CZA-ATM) are suggested, based on limited but promising clinical data.

Summary: PK/PD data and controlled clinical studies are needed to optimize current treatment options. Presently, combination therapy of SXT, LVX, MIN, or FDC, or monotherapy with CZA-ATM are recommended therapeutic options for severe-to-moderate S. maltophilia infections.

PubMed Disclaimer

References

    1. Abda EM, Krysciak D, Krohn-Molt I, et al. Phenotypic heterogeneity affects Stenotrophomonas maltophilia K279a colony morphotypes and β-lactamase expression. Front Microbiol 2015; 6:1373.
    1. Brooke JS. Stenotrophomonas maltophilia : an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25:2–41.
    1. Chang YT, Lin CY, Chen YH, et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol 2015; 6:893.
    1. Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia : an emerging opportunist human pathogen. Lancet Infect Dis 2009; 9:312–323.
    1. Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis 2014; 59: (Suppl 5): S335–S339.